The CLL-17 study, comparing continuous ibrutinib to time-limited therapies, showed overlapping efficacy. Its main impact wasn't declaring a winner, but affirming that oncologists can base treatment decisions on patient preference for continuous vs. fixed-duration therapy, knowing outcomes will be similar.

The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.

For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."

Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.

The SEQUOIA study showed that for high-risk CLL patients (e.g., p53 mutated), extending treatment with zanubrutinib and venetoclax beyond the planned duration significantly increases rates of undetectable MRD. This suggests a personalized, response-adapted approach, challenging the rigid concept of "fixed-duration" for all.

The CLL-17 trial, the first modern head-to-head comparison of major CLL strategies, showed no difference in 3-year survival between fixed-duration and continuous therapy. This landmark finding provides strong evidence that stopping treatment is a safe and effective strategy that reduces long-term toxicity for patients.

Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.